Literature DB >> 14767458

Effect of omalizumab in health care workers with occupational latex allergy.

Francisque Leynadier, Ouafia Doudou, Hafida Gaouar, Vincent Le Gros, Isabelle Bourdeix, Laurence Guyomarch-Cocco, Patrick Trunet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14767458     DOI： 10.1016/j.jaci.2003.11.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  13 in total

Review 1.  Occupational Latex Allergy: the Current State of Affairs.

Authors:  Olivier Vandenplas; Monika Raulf
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

Review 2.  Omalizumab : other indications and unanswered questions.

Authors:  Vaishali S Mankad; A Wesley Burks
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

3.  [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].

Authors:  J Schmitt; K Schäkel
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

Review 4.  Monoclonal antibodies and other biologic agents in the treatment of asthma.

Authors:  Aidan A Long
Journal:  MAbs       Date:  2009-05-04       Impact factor: 5.857

5.  Postpartum collapse.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2019-12-06

6.  Targeting immunoglobulin E as a novel treatment for asthma.

Authors:  Thomas Sandström
Journal:  Curr Allergy Asthma Rep       Date:  2005-03       Impact factor: 4.919

Review 7.  Anti-IL5 therapies for asthma.

Authors:  Hugo A Farne; Amanda Wilson; Colin Powell; Lynne Bax; Stephen J Milan
Journal:  Cochrane Database Syst Rev       Date:  2017-09-21

8.  Omalizumab in the management of patients with allergic (IgE-mediated) asthma.

Authors:  Thomas Sandström
Journal:  J Asthma Allergy       Date:  2009-05-08

9.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

10.  Inhibition of IgE Activity to Bind its High Affinity Receptor (FcεRIα) by Mouse Anti-IgE Cε3∼4 Monoclonal Antibody (QME5).

Authors:  Chun Xia Qiao; Ming Lv; Lei Ming Guo; Ming Yu; Yan Li; Zhou Lin; Xiao Li Hua; Chun Mei Hou; Jian Nan Feng; Bei Fen Shen
Journal:  Int J Biomed Sci       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.